Short-Term Debt to Equity Ratio: Protagenic Therapeutics, Inc. (PTIX)
The price action visualization for Protagenic Therapeutics (PTIX) on the GURU.Markets platform shows the metric at 0.00, while the business leverages executive expertise in the CNS field and strict control over R&D costs. Protagenic Therapeutics (PTIX) is currently launching primary clinical trials for new psychiatric disorder treatments to attract investment, which will culminate in the release of safe peptide-based antidepressants.
Protagenic - analytical breakdowns and key metrics (PTIX)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Protagenic Therapeutics|PTIX - Long-Term Liabilities to Equity|Short-Term Debt to Equity Protagenic Therapeutics|PTIX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Protagenic Therapeutics Inc.|PTIX - Long-Term Debt|Company Current Liabilities Protagenic Therapeutics|Quick Ratio protagenic.com
- company profitability and valuation multiples indicators:
Fundamental valuation:PTIX Protagenic Therapeutics, Inc.
Developing synthetic peptides to combat depression within strict ESG standards, Protagenic Therapeutics (PTIX) maintains financial stability through liability control, where the current value of 0.00 reflects the ratio of short-term loans to net equity, allowing investors to assess liquidity risk and the company's solvency by tracking the dynamics of debt under one year relative to equity.
Competitors of Protagenic Therapeutics (PTIX)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amylyx AMLX|Trevi Corp (TRVI) - Current Liabilities to Capital|PRAX: Short-Term Debt to Equity Ratio|anavex.com - Short-Term Loans to Capital Ratio|CBLL: Short-Term Debt to Capital|Prothena Biosciences (PRTA) - Short-Term Debt to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|ANNX - Short-Term Indebtedness to Equity|Short-Term Debt to Capital OMER|NGNE - Current Liabilities to Capital|Short-Term Debt to Equity AC Immune SA ACIU|VYGR: Short-Term Debt to Capital Ratio|Neumora Therapeutics Inc - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Scilex Holding Company, Inc. SCLX|TVGN: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alpha Cognition Inc.|Short-Term Debt to Equity Ratio CGTX|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio SAVA (Cassava)|Short-Term Loans to Capital Ratio ASRT|Short-Term Debt to Capital COYA (Coya Therapeutics)|Ratio of Short-Term Indebtedness to Capital VTGN|Ovid Rx - Short-Term Debt to Capital|Current Liabilities to Capital Acumen Pharmaceuticals Inc.|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Alterity Therapeutics Limited - Ratio of Short-Term Indebtedness to Capital|CLNN (Clene Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital PepGen Corp|Short-Term Debt to Equity Jupiter Neurosciences (JUNS)|RLMD: Current Liabilities to Equity|Short-Term Debt to Capital ANVS (Annovis Bio Corp)|Grace Therapeutics Inc (GRCE) - Current Liabilities to Capital|AIFF: Short-Term Debt to Equity Ratio|KLTO - Short-Term Debt to Capital|NRSN (neurosense-tx.com) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Loans to Capital Ratio|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|NeurAxis Inc (NRXS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital HSDT|Short-Term Debt to Equity Ratio passagebio.com PASG|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|Short-Term Debt to Capital Coefficient Minerva Neurosciences Inc (NERV)|ATHA - Short-Term Debt to Equity|Current Liabilities to Equity ADXN|ALZN (alzamend.com) - Short-Term Debt to Equity Ratio|CYCN: Short-Term Loans to Capital Ratio|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Cortigent Medical (CRGT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO: Short-Term Debt to Capital Ratio|Eliem - Short-Term Debt to Capital|Current Liabilities to Capital Intra-Cellular Therapies|LBPH (Longboard Pharma) - Short-Term Debt to Equity Ratio|Marinus Pharma (MRNS) - Short-Term Debt to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX - Current Liabilities to Capital|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL (Vigil Neuroscience Inc.) - Current Liabilities to Equity|WENA - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)